Abacavir + Efavirenz + LamivudineThird Party Manufacturing in India

This triple combination works by simultaneously blocking the HIV-1 reverse transcriptase enzyme through two distinct mechanisms.

Abacavir and Lamivudine act as nucleoside reverse transcriptase inhibitors (NRTIs), terminating the viral DNA chain after being incorporated. Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), binds directly to the reverse transcriptase enzyme, inducing a structural change that disrupts its catalytic site.

Unlike regimens requiring multiple pills, this complete regimen in a single tablet offers powerful suppression of viral replication. It is highly effective and well-tolerated for treatment-naive and experienced patients managing HIV-1 infection.

Therapeutic Uses

This triple combination is prescribed for the treatment of:

• HIV-1 Infection: Serves as a complete antiretroviral regimen in a single daily dose.
• Viral Suppression: Rapidly decreases viral load and helps maintain long-term virologic suppression.
• Immune Reconstitution: Promotes the recovery of CD4+ T-cell counts, reducing the risk of AIDS-defining illnesses.

Why Manufacturers Choose This Combination

Fixed-dose combinations (FDCs) are the gold standard in modern HIV therapy due to their ability to maximize patient adherence. Formulating three distinct APIs into a stable, single tablet requires advanced manufacturing capabilities.

This makes the Abacavir, Efavirenz, and Lamivudine combination one of the most sought-after products for third party manufacturing in India, with strong demand from global health initiatives, export markets, and specialized institutional buyers.